磁共振动态增强检查及生物学因子对乳腺浸润性导管癌新辅助化疗疗效的分析研究

Abstract
Figure/Table
References
Related Citation (3)

Download: PDF (0 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To evaluate the effect of neoadjuvant chemotherapy (NAC) with 3.0 T dynamic enhanced magnetic resonance imaging (DCE-MRI) in breast invasive ductal carcinoma and analyze whether the change of biological factors can predict the effect of NAC.Methods Thirty-three patients of breast invasive ductal carcinoma underwent DCE-MRI examination before and after NAC;lesions were performed pathological examination before and after NAC.Lesion morphology,margin,lumpy or not,enhanced features and largest diameter reduction rate were analyzed before and after NAC.After NAC,according to the response evaluation criteria of solid tumors (RECIST),the patients were divided into effective and invalid groups,and the difference of the maximum diameter reduction rate of the two groups was tested by independent sample t test.The changes of expression levels of estrogen receptor (ER),progesterone receptor (PR), human epidermal growth factor receptor 2 (Her-2) and cell value-added nuclear antigen (Ki67) before and after NAC were analyzed.Results There was no significant difference in the shape and intensifying characteristics of breast cancer before and after NAC (P＞0.05).There was a statistically significant difference in TIC type before and after NAC (P＜0.05).In 33 patients, effective group of 23 cases,10 cases of invalid group.The largest diameter reduction rate of effective group was (61.31+20.13) %,invalid group was (17.06+10.21) %,the largest diameter reduction rate of the two group was compared,there was significant difference (P=0.000).Compared the expression levels of ER,PR,Her-2, Ki67 before and after NAC, there were no significant differences in ER,PR,Her-2 (P＞0.05),there were statistically significant differences in the changes of Ki67 (P=0.028).Conclusion 3.0T DCE-MRI can monitor the size,shape and enhancement characteristics of breast cancer during NAC.It can be used for preoperative evaluation of residual lesions after NAC,and combined with changes in biological factors,to predict the effect of NAC.

Key words： breast cancer magnetic resonance imaging dynamic enhancement neoadjuvant chemotherapy biological factors

Received: 27 April 2018

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	DONG Jingmin
	XU Kun
	BIAN Jia
	WANG Hongxia
	REN Wen
	SU Wenjing
	QU Zhengwei
	ZHONG Xiaofei

Cite this article:

DONG Jingmin,XU Kun,BIAN Jia, et al. Effect of dynamic enhanced magnetic resonance imaging and biological factors in neoadjuvant chemotherapyfor invasive ductal carcinoma of breast[J]. 滨州医学院学报, 2018, 41(4): 284-288.

URL:

http://manu58.magtech.com.cn/Jwk_bzyxy/EN/ OR http://manu58.magtech.com.cn/Jwk_bzyxy/EN/Y2018/V41/I4/284

[1] Torre L A,Bray F,Siegel R L,et al.Global cancer statistics,2012[J].CA Cancer J Clin,2015,65(2):87-108.
[2] Chakrabarti S,Mandal P K,Chowdhury A R,et al.Consequence of neo-adjuvant chemotherapy on morphology of breast carcinoma: A systematic evaluation[J].Indian J Cancer,2016,53(1):29-33.
[3] Sturgeon C M,Duffy M J,Stenman U H,et al.National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for Use of Tumor Markers in Testicular,Prostate,Colorectal,Breast, and Ovarian Cancers.Clinical Chemistry[J].2008,54(12):11-79.
[4] Kuhl C K,Mielcareck P,Klaschik S,et al.Dynamic breast MR imaging:are signal intensity time course data useful for differential diagnosis of enhancing lesions[J].Radiology,1999,211(1):101-110.
[5] Eisenhauer E A,Therasse P,Bogaerts J,et al.New response evaluation criteria in solid tumours:revised RECIST guideline (version 11)[J].Eur J Cancer,2009,45(2):228-247.
[6] 张静,程流泉,安宁豫,等.磁共振扩散加权成像评估乳腺癌新辅助化疗疗效[J].中国医学影像技术,2011,27(6):1145-1149.
[7] Mayrhofer R M,Ng H P,Putti T C,et al.Magnetic resonance in the detection of cancers of different histological types[J].Magn Reson Insights,2013,6(6):33-49.
[8] Abramson R G,Arlinghaus L R,Weis J A,et al.Current and emerging quantitive magnetic reasonance imging methods for assessing and predicting the response of breast cancer to neoadjuvant therapy[J].Breast Cancer (Dov Med Press),2012,2012(4):139-154.
[9] Choi E J,Choi H,Choi S A,et al.Dynamic contrast-enhanced breast magnetic resonance imaging for the prediction of early and late recurrences in breast cancer[J].Medicine,2016,95(48):5330.
[10] 李洁,张晓鹏,陆爱萍,等.乳腺癌新辅助化疗后动态增强MRI表现与病理反应性相关性研究[J].中华放射学杂志,2007,41(11):1200-1204.
[11] 周娟,邢旭东,李功杰,等.动态增强磁共振成像对新辅助化疗后乳腺癌残余病灶的术前评估[J].实用放射学杂志,2012,28(10):1553-1556.
[12] Yoshida A,Hayashi N,Suzuki K,et al.Change in HER2 status after neoadjuvant and the prognostic impact in patients with primary breast cancer[J].J Surg Oncol,2017,116(8):1021-1028.
[13] Battista M J,Mantai N,Sicking I,et al.Ki-67 as an independent prognostic factor in an unselected cohort of patients with ovarian cancer:results of an explorative, retrospective study[J].Oncol Rep,2014,31(5):2213-2219.
[14] Yerushalmi R,Woods R,Ravdin P M,et al.Ki67 in breast cancer:prognostic and predictive potential[J].Lancet Oncol,2010, 11(2):174-183.
[15] Bottini A,Berruti A,Bersiga A,et al.Relationship between tumour shrinkage and reduction in Ki67 expression after primary chmotherapy in human breast cancer[J].Br J Cancer,2001,85(8):1106-1112.